Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological or cytological diagnosis of lung adenocarcinoma histology with brain metastases~2. 18 years or older~3. Eastern Cooperative Oncology Group (ECOG) Performance Status no more than 3 (poor PS caused by neurological symptom)~4. Appraisable intracranial disease, the presence of at least one lesion, and the longest diameter \> 5 mm by brain MRI~5. Haemoglobin 10.0 g/dl, Absolute neutrophil count (ANC) 1.5\^9/L, platelets 100 x 10\^9/L~6. Total bilirubin 1.5 x upper limit of normal (ULN)~7. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN in the absence of liver metastases, or \< 5 x ULN in case of liver metastases~8. Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula)~9. If received brain radiotherapy, patients included at least 8 weeks after the end of radiotherapy.~Exclusion Criteria:~1. Mixed non-adenocarcinoma cell lung cancer histology~2. Previous treatment with pemetrexed or tarceva~3. Be allergic to pemetrexed or tarceva

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib, pemetrexed, cisplatin (Type: EXPERIMENTAL): None
- erlotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).